Articles from Medicus Pharma Ltd

The Company is expected to finalize the Clinical Study Report (CSR) in Q2 2026 to support planned end of Phase 2 (EOP2) meeting with the FDA

Company Exec. Chairman & CEO in a fireside chat is expected to highlight the role of Skinject in an autosomal dominant rare disease, AI-enabled drug development strategy and partnering readiness

The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and a first in class product for Acute Urinary Retention Relapse prevention (AURr) collectively representing ~US$6 billion in potential market opportunity

Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control

The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as SKNJCT-003 study approaches database lock, topline clinical data readout and partnering readiness

The Company’s abstract, Evaluation of Teverelix in Healthy Female Volunteers, has been accepted for presentation at American Association of Clinical Endocrinology (AACE) Annual meeting 2026

The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market opportunities, an AI-enabled development strategy, and regulatory optionality

THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026